US Broker Ratings

uniQure N.V. (QURE) Stock Report: Exploring a 123.60% Potential Upside in the Biotech Sector

uniQure N.V. (NASDAQ: QURE), a prominent player in the biotechnology sector, has caught the attention of investors with its significant potential upside of 123.60%, according to recent analyst ratings. Focused..

GH Research PLC (GHRS) Stock Analysis: A Biotech with 152.67% Potential Upside

GH Research PLC (NASDAQ: GHRS) has captured the attention of investors with its promising potential upside of 152.67%. This Dublin-based biotechnology firm, specializing in innovative treatments for depression, has shown..

Regulus Therapeutics Inc. (RGLS) Investor Outlook: What the -14.22% Potential Downside Means for Shareholders

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biotechnology firm focused on developing innovative therapies to combat genetically based orphan diseases. Headquartered in San Diego, California, the company specializes in drugs..

Talkspace, Inc. (TALK) Stock Analysis: Breaking Down the 76% Potential Upside

Talkspace, Inc. (NASDAQ: TALK), a prominent player in the digital mental health space, offers a compelling case for investors seeking exposure to the burgeoning healthcare technology sector. With its innovative..

AMN Healthcare Services Inc (AMN) Stock Analysis: Evaluating the 3.24% Potential Upside Amidst Sector Challenges

AMN Healthcare Services Inc (NYSE: AMN), a prominent name in the healthcare sector, is catching the eye of investors with a potential upside of 3.24%. Despite the challenges reflected in..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: A 72.59% Potential Upside Sparks Investor Interest

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a healthcare company based in San Diego, California, specializing in biotechnology. With a market cap of $874.85 million, Maravai LifeSciences plays a pivotal..

Delcath Systems, Inc. (DCTH) Stock Analysis: A 133% Potential Upside and Strong Buy Ratings in the Medical Device Sector

Delcath Systems, Inc. (NASDAQ: DCTH) is drawing significant attention in the healthcare sector, particularly within the medical devices industry. With a market capitalization of $364.16 million, this New York-based interventional..

Nurix Therapeutics (NRIX) Stock Analysis: Unveiling a 209% Potential Upside in Biotech

Nurix Therapeutics, Inc. (NRIX), a burgeoning player in the biotechnology industry, presents a compelling case for investors eyeing high-growth opportunities in the healthcare sector. Based in San Francisco, this clinical-stage..

Vir Biotechnology, Inc. (VIR) Stock Analysis: A Look at the 302% Potential Upside

Vir Biotechnology, Inc. (NASDAQ: VIR), a clinical-stage biopharmaceutical company, has captured the attention of investors with an eye-popping potential upside of 302.40%. With a market capitalization of $608.45 million, this..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech Bet with 143% Upside Potential

Immunome, Inc. (NASDAQ: IMNM) is making waves in the biotechnology sector, offering exciting prospects for investors looking to capitalize on its burgeoning pipeline of cancer therapies. With a market cap..

InnovAge Holding Corp. (INNV) Stock Analysis: A 44.93% Potential Upside Despite Challenges

InnovAge Holding Corp. (NASDAQ: INNV) stands out in the healthcare sector as a unique player focusing on the needs of seniors through its PACE (Program of All-Inclusive Care for the..

Neuropace, Inc. (NPCE) Stock Analysis: A Look at the 94% Potential Upside for Investors

Neuropace, Inc. (NASDAQ: NPCE) is capturing attention in the healthcare sector, particularly within the medical devices industry, as its innovative solutions target a critical unmet need in epilepsy treatment. With..

Niagen Bioscience, Inc. (NAGE): Biotech Stock with a 64% Upside Potential

Investors with an eye on the healthcare sector may find Niagen Bioscience, Inc. (NASDAQ: NAGE) a compelling opportunity. With a market capitalization of $779.19 million and a focus on developing..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Exploring a Potential 110% Upside in Biotechnology

For individual investors with an appetite for high-risk, high-reward stocks, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) offers a tantalizing opportunity. With a potential upside of over 110%, according to analyst ratings,..

Phibro Animal Health Corporation (PAHC) Stock Analysis: Navigating Growth Amidst Potential Challenges

Phibro Animal Health Corporation (NASDAQ: PAHC), a prominent player in the healthcare sector, primarily focuses on the production and distribution of animal health and mineral nutrition products. With a market..

Spyre Therapeutics, Inc. (SYRE): Investor Outlook Reveals 221% Potential Upside in Biotech Sector

Spyre Therapeutics, Inc. (NASDAQ: SYRE) is capturing investor attention with a staggering potential upside of 221.22%, as analysts remain bullish on this clinical-stage biotechnology firm. Focused on addressing unmet needs..

AbCellera Biologics Inc. (ABCL) Stock Analysis: Unpacking a Potential 115.95% Upside

Investors with a keen eye on the biotechnology sector might want to turn their attention to AbCellera Biologics Inc. (NASDAQ: ABCL), a Canadian biotech firm making waves in the healthcare..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: Aiming for a 237.47% Potential Upside

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) is making waves in the biotechnology sector with its ambitious approach to developing breakthrough treatments for both pediatric and adult diseases. As a commercial-stage..

Investor Outlook: Praxis Precision Medicines, Inc. (PRAX) Sees Potential 114.89% Upside Amid Strong Buy Ratings

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a Boston-based biotechnology company, is garnering attention in the healthcare sector for its innovative approach to treating central nervous system (CNS) disorders. Despite the..

Fulgent Genetics, Inc. (FLGT) Investor Outlook: Unveiling an 18% Upside Potential

For investors navigating the vast terrain of healthcare stocks, Fulgent Genetics, Inc. (NASDAQ: FLGT) presents an intriguing case with a potential upside of 18.41%, according to recent analyst ratings. As..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds